Bolt Biotherapeutics

Unleashing the power of the immune system to achieve anti-tumor immunity for the nearly 80% of patients who are unresponsive to checkpoint inhibitors.

[Bolt Biotherapeutics @BoltBio]

Today #BoltBio reported financial results for the fourth quarter & full year 2025 and provided corporate updates. Learn more: https://t.co/KUfngdOlpP

[Bolt Biotherapeutics @BoltBio]

Our team is looking forward to attending the 46th Annual Health Care Conference hosted by TD Securities, as well as the Global Healthcare Conference hosted by Leerink Partners next month. Learn more about our participation in today's press release: https://t.co/ir9BHAODj8

[Bolt Biotherapeutics @BoltBio]

Today #BoltBio reported financial results for the third quarter and provided corporate updates. Learn more: https://t.co/aWtRCs4k6M

[Moffitt Cancer Center @MoffittNews]

Live from #SITC25: Justin Kenkel, PhD (@BoltBio) presents a novel PD-L1–directed Immune Stimulatory Antibody Conjugate (ISAC) that activates both innate and adaptive immunity to fight cancer.

Key takeaways:
• Unlike standard PD-L1 blockers, this ISAC delivers a TLR agonist to PD-L1⁺ myeloid cells, activating macrophages and dendritic cells.
• Induces cytokine release and repolarizes the tumor microenvironment from immunosuppressive to immune-stimulatory.
• Promotes T-cell priming and durable anti-tumor responses in preclinical models.
• Offers a promising strategy to overcome resistance to current PD-1/PD-L1 therapies.

#MoffittSITC25 @sitcancer

[Bolt Biotherapeutics @BoltBio]

Today #BoltBio reported financial results for the second quarter and provided corporate updates. Learn more: https://t.co/4AIqcYT0xg

[Bolt Biotherapeutics @BoltBio]

Today #BoltBio reported financial results for the first quarter and provided corporate updates. Learn more: https://t.co/suymm9Uxpj

[Bolt Biotherapeutics @BoltBio]

Join us at 2:30pm PT / 5:30pm ET today for a webcast KOL event discussing the Phase 1 dose-escalation results from our clinical study of BDC-3042. Our team will also share an update on our collaborations and clinical development plans. Tune in here: https://t.co/QvJacYOvPC

[Bolt Biotherapeutics @BoltBio]

Join us on Monday, May 12, 2025, for a webcast KOL event discussing the Phase 1 dose-escalation results from our clinical study of BDC-3042. Our team will also share an update on our collaborations and clinical development plan for BDC-4182. Learn more: https://t.co/PgVRGOEuR7

[Bolt Biotherapeutics @BoltBio]

Today, we're presenting data from our next-generation Boltbody™ #ISACs targeting CEA and PD-L1 at #AACR25! We're encouraged by these early results and are excited about this compelling new approach to treat #cancer. Read our press release here: https://t.co/XqutYCnZzm

[Bolt Biotherapeutics @BoltBio]

We're at #AACR25 presenting data from our Phase 1 dose-escalation study of BDC-3042. We’re also sharing data from our PD-L1 targeting #antibody and CEA-targeted #ISAC programs. Stop by our posters to learn more and read the BDC-3042 press release here: https://t.co/Se90hk1Dwf

[Bolt Biotherapeutics @BoltBio]

We're presenting data from our Phase 1 dose-escalation clinical study of BDC-3042 at the @AACR annual meeting! Read our press release for more details on our poster presentations: https://t.co/EqGvZufjzO. #AACR25 #immunooncology #colorectalcancer #lungcancer #pancreaticcancer

[Bolt Biotherapeutics @BoltBio]

Today #BoltBio reported financial results for the fourth quarter & full year 2024 and provided corporate updates. Learn more: https://t.co/4GaD6qkBCI

[Bolt Biotherapeutics @BoltBio]

According to @AmericanCancer, #ColorectalCancer is the 3rd most common cancer worldwide. At Bolt, we’re developing our dectin-2 targeting antibody, BDC-3042, for the potential treatment of CRC. Learn more about our work: https://t.co/9CeTY2E1im

[Bolt Biotherapeutics @BoltBio]

Today with our collaborators at Toray Industries, we announced that the target of our worldwide co-development collaboration is Toray-discovered Caprin-1. This co-developed Boltbody™ #ISAC will be applicable to multiple solid tumor types. Learn more: https://t.co/zeiucMtfP0

[Bolt Biotherapeutics @BoltBio]

Today, #BoltBio commemorates #MLKDay. We are continuously inspired by Dr. King’s commitment to justice and challenge ourselves to examine ways we can contribute to creating a more equitable world both professionally and personally.

[Bolt Biotherapeutics @BoltBio]

Our team is looking forward to being in San Francisco for #JPMWeek to connect with the #biotech community and discuss our novel immunotherapies for the treatment of #cancer. #ISAC #ImmunoOncology #JPM25

[Bolt Biotherapeutics @BoltBio]

From our #TeamBolt family to yours, we’re wishing you a happy, healthy, and safe holiday season! Thank you for following our story as we progress our mission to leverage the immune system for a better way to treat cancer. Here's to an exciting 2025!

[Bolt Biotherapeutics @BoltBio]

Earlier this month, our Senior Director and Program Team Lead, Shelley Ackerman, presented the advantages of next-generation #ISACs at @World_ADC San Diego conference! #TeamBolt #CancerResearch #Immunooncology

[Bolt Biotherapeutics @BoltBio]

Today #BoltBio reported financial results for the third quarter and provided corporate updates. Learn more: https://t.co/xeLwD5Akhs

[Bolt Biotherapeutics @BoltBio]

September 24th is #WorldCancerResearchDay! Our talented team at #BoltBio is dedicated to the discovery and development of transformative treatments that leverage the immune system for a better way to treat cancer. Learn more about our science: https://t.co/uaF30Mdpd1